Form 4: Scholar Rock General Counsel Receives Significant Equity Grant

Scholar Rock Holding Corp.'s General Counsel, Junlin Ho, was granted 8,571 restricted stock units and 11,429 stock options, aligning executive incentives with shareholder value.

Summary

• Junlin Ho, General Counsel of Scholar Rock Holding Corp. (SRRK), acquired 8,571 shares of common stock through Restricted Stock Units (RSUs) and 11,429 stock options on June 9, 2025.
• The RSUs represent the contingent right to receive one share of common stock upon vesting, with vesting occurring in four annual installments over four years, with the first installment vesting on May 15, 2026.
• The stock options have an exercise price of $34.07 and vest in sixteen quarterly installments over four years, with the first installment vesting on August 12, 2025, and an expiration date of June 9, 2035.
• Following these transactions, Junlin Ho beneficially owns a total of 230,011 shares of common stock, which includes 97,923 direct shares and 132,088 RSUs.
• Additionally, 11,429 derivative securities (stock options) are beneficially owned directly.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to an executive, which is a positive for aligning management incentives with shareholder interests, but it does not contain information that would significantly alter the company's fundamental outlook or financial performance.

Positives

• The grant of Restricted Stock Units (RSUs) and stock options aligns the General Counsel's financial interests directly with the long-term performance and shareholder value of Scholar Rock Holding Corp.
• Equity compensation is a standard practice to incentivize key executives and promote retention, fostering a commitment to the company's success.

Risks

• The vesting of both RSUs and stock options is contingent upon the reporting person's continued service relationship with the Issuer, meaning unvested equity could be forfeited upon departure from the company.

Future Outlook

The vesting schedules for the granted RSUs and stock options extend over four years, indicating an expectation of continued service from the General Counsel and a long-term incentive structure tied to the company's future performance and strategic objectives.

Industry Context

The granting of equity compensation, such as Restricted Stock Units (RSUs) and stock options, to key executives is a common and widely accepted practice within the biotechnology and pharmaceutical industries. This approach is used to attract, retain, and motivate top talent by aligning their financial incentives with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• While specific compensation packages vary widely based on company size, stage, and executive role, the use of RSUs and stock options as a significant component of executive compensation is standard across the biotech sector.
• Companies like Biogen, Vertex Pharmaceuticals, and Moderna frequently utilize similar equity-based incentives for their senior leadership to foster long-term commitment and performance alignment.
• The four-year vesting period for both RSUs and options is also a common structure designed to encourage executive retention and sustained focus on company growth.

Stakeholder Impact

• Shareholders: The equity grants align the General Counsel's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs within the company.

Next Steps

• Continued service of the General Counsel with Scholar Rock Holding Corp. for the vesting of RSUs and stock options.
• Future annual and quarterly vesting events for the granted equity as per the established schedules.

Key Dates

Keywords

Scholar Rock Holding Corp, SRRK, Form 4, Insider Trading, Equity Grant, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Beneficial Ownership, Corporate Governance